top of page

Junto Magazine


Virtual Reality and AI Entertainment: Startup Opportunities
Virtual reality and AI in entertainment are rapidly redefining how we conceive, produce, and consume content. More and more startups and independent studios are leveraging accessible tools to create immersive experiences that once required Hollywood-scale infrastructure and budgets. In this scenario, the ability to combine empathy, creativity, and technology becomes the driving force behind innovation, opening tangible opportunities for anyone looking to turn ideas into tangi
Marc Griffith
4 hours ago4 min read


Funding for Incubators and Accelerators 2026: Opportunities and Deadlines for Startups – Focus on Incubator and Accelerator Funding 2026
In the dynamic innovation ecosystem, funding for incubators and accelerators represents a practical lever to empower startups and technology transformation projects. For 2026, several regional and national-level developments aim to strengthen the incubation and acceleration system, offering concrete tools, clear criteria, and a relatively defined pathway to access resources. This article analyzes in detail a regional call aimed at Emilia-Romagna and offers actionable guidance
Marc Griffith
1 day ago2 min read


Crowdfunding in the EU 2025 ESMA Data: Trends, Volumes and Impacts on Startups and Investors
The European crowdfunding market is solidifying its position as a structural financing channel for startups and SMEs, according to ESMA in the report Crowdfunding in the EU 2025. The analysis, based on 2024 data, highlights significant figures: 181 authorized providers raised over €4.25 billion across 21 Member States. A system on the rise and consolidation In 2024, loan-based crowdfunding remains the backbone of the sector, with 58% of the capital raised flowing into loan-ba
Marc Griffith
2 days ago5 min read


ECM therapies funding: Engitix closes €21 million extension for cancer and fibrosis
Engitix, a British biotech focused on the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, has announced the closing of a Series A extension of €21 million. The new capital comes from investors including Netherton Investments, a fund managed on behalf of Mike Platt, co-founder and managing director of BlueCrest Capital Management. This move marks a significant moment in the European biotech landscape, where large-scale ECM data usage and
Marc Griffith
3 days ago4 min read
bottom of page
